Applications of Fmoc-(R)-3-Amino-4-(3-Benzothienyl)-Butyric Acid in Industrial Manufacturing

As the direct manufacturer of Fmoc-(R)-3-Amino-4-(3-Benzothienyl)-Butyric Acid, we supply this protected amino acid derivative for advanced synthesis processes in biomolecular research and pharmaceutical production. Below, we detail its established industrial applications, compliance frameworks, usage recommendations, integration points, and end product categories.

1. Peptide API Intermediate Synthesis

Leading pharmaceutical manufacturers rely on this compound as a chiral building block for selective peptide API intermediate synthesis, especially where noncanonical amino acids are required to introduce sulfur-containing heterocycles. Control over stereochemistry and side-chain functionality enables the preparation of peptide drug candidates with enhanced pharmacological profiles, including improved metabolic stability and receptor selectivity.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapters: Residual Solvents, Elemental Impurities
• EDQM CEP requirements for peptide intermediates
• FDA 21 CFR Part 211 for finished pharmaceuticals

Typical usage ratio

• 0.4 – 1.1 equivalents per peptide coupling, based on sequential chain elongation and protecting group removal strategies; adjust ratio for solution vs. solid-phase synthesis routes.

Downstream process integration

• Monomer solution or resin pre-loading step in automated peptide synthesizers.
• Fmoc group removal under basic conditions, followed by amide bond formation to extend peptide chains.
• Enters HPLC purification process for quality and identity confirmation before final peptide product assembly.

Final product types

• Investigational peptide APIs with non-standard residues
• Specialty oligopeptides for metabolic or receptor targeting
• Generic and research-grade peptide libraries

2. Drug Discovery Screening Peptides

Contract research organizations and biotech platforms incorporate this aromatic-butyl side-chain containing amino acid in the design of high-diversity peptide screening libraries. The benzothienyl functionality provides specific π-π stacking, enabling candidates with unique target-binding motifs in early-stage drug discovery, particularly where sulfur heterocycles mimic endogenous ligands or disrupt protein-protein interactions.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• Synthetic peptide ISO 13485:2016 for medical device research
• Sigma Aldrich Custom Peptides Product Specifications
• IUPAC peptide nomenclature for library synthesis recordkeeping

Typical usage ratio

• 0.75 – 1.0 molar equivalents per chain position when introducing into combinatorial pools; frequency varies by target-driven design strategy.

Downstream process integration

• Fmoc-protected amino acid dispensed directly into parallel solid-phase synthesis reactors or automated synthesizer wells.
• After chain elongation, proceeds through pooled cleavage and final library deprotection.
• Fractions subjected to analytical LC-MS or affinity screening for target binding analysis.

Final product types

• Peptide combinatorial libraries for high-throughput screening
• Lead-optimization peptides with sulfur-heterocyclic modification
• Affinity reagents for protein interaction studies

3. Structural Biology and Analytical Peptide Standards

Research laboratories synthesize reference peptides incorporating this enantiomeric amino acid to investigate protein folding, conformational motifs, and structure-activity relationships. The specific R-stereochemistry and benzothienyl moiety enable NMR, crystallography, and chromatographic method development, supporting structural validation and impurity profiling across biomolecular research programs.

Industry compliance standards

• ISO/IEC 17025 for calibration laboratory competence
• USP General Chapter <621> Chromatography
• GMP guidelines for analytical reference material production
• Journal of Proteome Research reporting standards

Typical usage ratio

• 0.1 – 2.0 molar equivalents per sequence; level selected based on desired reference peptide length and experimental design.

Downstream process integration

• Batch peptide synthesis with incorporation of the protected derivative at defined positions.
• Purification by preparative HPLC and lyophilization for solid-state study or standard preparation.
• Reference standards stored under validated, monitored conditions for inter-laboratory reproducibility.

Final product types

• Analytical peptide standards for HPLC/LC-MS calibration
• Structure-probing reference peptides for NMR/X-ray studies
• Training standards for instrument performance validation

4. Specialty Modified Peptide Therapeutics

Biopharma manufacturers utilize this compound in the custom production of modified peptide therapeutics where introducing rigidified aromatic structures enhances selectivity, extends biological half-life, or promotes blood–brain barrier penetration. Fmoc-(R)-3-Amino-4-(3-Benzothienyl)-Butyric Acid supports the synthesis of advanced peptide drug candidates for orphan indications, neurology, and selective enzyme inhibition, requiring stringent quality and traceability controls during GMP manufacturing.

Industry compliance standards

• EU GMP Part II for active substance manufacture
• USP <1047> Compliance for Biotechnology-Derived Therapeutic Peptides
• FDA Guidance for Industry: Q11 Development and Manufacture of Drug Substances
• ICH Q3A/B for impurity and heavy metal control

Typical usage ratio

• 1.0 equivalent per incorporation position; total varies by peptide length and modification density, often between 1% – 5% of total amino acid content in a batch.

Downstream process integration

• Fmoc-protected monomer integrated into fully automated GMP peptide synthesis process flows
• Critical reagent tracking through ERP and batch records
• Lot-specific analytical verification of final peptide for release

Final product types

• Modified therapeutic peptides addressing receptor targets or metabolic pathways
• Innovation drugs in clinical phase development stages
• Custom peptides for personalized medicine platforms